Abstract
Neoadjuvant targeted therapy remained controversial for mutant early-stage NSCLC. Despite limited efficacy of immunotherapy for advanced NSCLC with driver mutations, whether induction immunotherapy could be feasible for these patients warrants further exploration.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
